BioCopy Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 39

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $11.4M

  • Investors
  • 3

BioCopy General Information

Description

Developer of a biomolecule copying technology designed for the production and replication of microarrays. The company's technology provides a shortcut to navigate the complexity of the immune system for future tumor and autoimmune therapy, which can be applied in diagnostics, vaccine development, as well as lead and hit screening, enabling clients to copy biomolecules analogous to a photocopier.

Contact Information

Website
www.biocopy.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Stücki Park
  • Hochbergerstrasse 60 Floor
  • 4057 Basel
  • Switzerland
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Stücki Park
  • Hochbergerstrasse 60 Floor
  • 4057 Basel
  • Switzerland

BioCopy Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioCopy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series A) 01-May-2026 $11.4M Completed Generating Revenue
5. Seed Round 15-Dec-2025 Completed Generating Revenue
4. Angel (individual) 27-Aug-2021 Cancelled Generating Revenue
3. Grant 01-Jun-2018 Completed Startup
2. Angel (individual) 01-Jan-2016 $2.18M $2.18M Completed Startup
1. University Spin-Out 01-Jan-2016 Completed Startup
To view BioCopy’s complete valuation and funding history, request access »

BioCopy Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
To view BioCopy’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

BioCopy Patents

BioCopy Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4837921-A1 Antigen binding proteins specifically binding mage-a3 Pending 09-May-2025
WO-2026234298-A1 Antigen binding proteins specifically binding mage-a3 Pending 09-May-2025
EP-4831636-A1 Improved immunopeptidome method to identify neoepitopes for cancer immunotherapy and neoepitopes as identified Pending 25-Apr-2025
WO-2026224094-A1 Improved immunopeptidome method to identify neoepitopes for cancer immunotherapy and neoepitopes as identified Pending 25-Apr-2025
EP-4810517-A1 Antigen binding proteins specifically binding mage-a4 Pending 21-Mar-2025 C07K16/30
To view BioCopy’s complete patent history, request access »

BioCopy Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioCopy Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Haute Capital Partners PE/Buyout Minority
EASME - EU Executive Agency for SMEs Corporation
The University of Freiburg University
To view BioCopy’s complete investors history, request access »

BioCopy Acquisitions (1)

BioCopy’s most recent deal was a Merger/Acquisition with Perspix Biotech. The deal was made on 09-Apr-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Perspix Biotech 09-Apr-2024 Merger/Acquisition Biotechnology
To view BioCopy’s complete acquisitions history, request access »

BioCopy FAQs

  • When was BioCopy founded?

    BioCopy was founded in 2016.

  • Where is BioCopy headquartered?

    BioCopy is headquartered in Basel, Switzerland.

  • What is the size of BioCopy?

    BioCopy has 39 total employees.

  • What industry is BioCopy in?

    BioCopy’s primary industry is Discovery Tools (Healthcare).

  • Is BioCopy a private or public company?

    BioCopy is a Private company.

  • What is BioCopy’s current revenue?

    The current revenue for BioCopy is .

  • How much funding has BioCopy raised over time?

    BioCopy has raised $24.6M.

  • Who are BioCopy’s investors?

    Haute Capital Partners, EASME - EU Executive Agency for SMEs, and The University of Freiburg have invested in BioCopy.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process